Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1546 to 1560 of 2548 results for methods

  1. SYNE-COV for predicting COVID-19 outcomes (MIB264)

    NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .

  2. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

  3. Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care (NG26)

    This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after by local authorities in foster homes (including kinship foster care), residential settings and other accommodation, or on the edge of care. It aims to address the many emotional and psychological needs of children and young people in these situations, including those resulting from maltreatment.

  4. Gout: diagnosis and management (NG219)

    This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

  5. Cirrhosis in over 16s: assessment and management (NG50)

    This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.

  6. Bronchiolitis in children: diagnosis and management (NG9)

    This guideline covers diagnosing and managing bronchiolitis in babies and children. It aims to help healthcare professionals diagnose bronchiolitis and identify if babies and children should be cared for at home or in hospital. It describes treatments and interventions that can be used to help with the symptoms of bronchiolitis.

  7. Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)

    Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.

  8. Endoscopic sleeve gastroplasty for obesity (IPG783)

    Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.

  9. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

  10. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)

    NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .

  11. The STAK tool for preventing and treating knee stiffness (MIB252)

    NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .

  12. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.

  13. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

  14. What is the most clinically and cost-effective treatment for diverticular disease?

    disease or people's quality of life. The committee used formal consensus methods together with their expertise and knowledge to make...

  15. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .